Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier ...

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

So where will Recursion be in five years, and is the stock worth buying today? There's a lot coming up Today, Recursion has no products approved for sale.

Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages artificial intelligence (AI), automation, and experimental biology to accelerate the discovery and development of new ...

Recursion Pharmaceuticals (RXRX) shares rallied 7.4% in the last trading session to close at $11.93. This move can be attributable to notable volume with a higher number of shares being traded ...

By Adriano Marchese Shares of Recursion Pharmaceuticals rose Tuesday morning after the company said slashing its workforce by 20% will extend its cash runway to the end of 2027.